CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Medical Officer sold 5,500 shares at $22.88 ($125,830)
- 144 Insider Sale of Securities
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Planned sale Chief Financial Officer sold 9,200 shares at $23.00 ($211,614)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Executive Officer sold 15,000 shares at $23.61 ($354,146)
- 144 Insider Sale of Securities
- 4 Planned sale President and COO sold 12,500 shares at $23.01 ($287,591)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Planned sale Chief Medical Officer sold 5,500 shares at $18.95 ($104,229)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Financial Officer sold 9,200 shares at $18.52 ($170,348)
Page 4 of 14 · 266 filings